Republished: DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis

Padron, Simonette; Rogers, Everett; Beckler, Michelle Demory; Kesselman, Marc M

doi:10.1136/dtb.2019.228981rep

Cited by 7 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By protecting inflammatory factors from enzymatic degradation by DPP-4, DPP4i could even potentiate some inflammatory network [43]. This is the mechanism postulated to form the basis for the development of arthritis during treatment with DPP4i [44,45], although this issue is still controversial [46]. Conflicting results were also detected in the observational studies included in this review.…”

Section: Discussionmentioning

confidence: 89%

Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis

Bonora

Avogaro

Fadini

2021

J Endocrinol Invest

View full text Add to dashboard Cite

Background The infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread all over the world, becoming pandemic. Several studies have shown that diabetes mellitus (DM) is an independent risk factor that increases mortality and other adverse outcomes of coronavirus disease-19 . Studies have suggested that SARS-CoV-2 may bind dipeptidyl peptidase-4 (DPP4) for entering cells of the respiratory tract. Besides, DPP4 takes part in immune system regulation. Thus, DPP-4 inhibitors (DPP4i) may play a role against COVID-19. Methods We focused on the impact of DPP4i treatment on COVID-19-related outcomes in people with DM. For this purpose, we conducted a systematic review and meta-analysis to summarize the existing evidence on this topic. Results Retrospective observational studies provide inconsistent results on the association between use of DPP4i and outcomes of COVID-19. While two studies reported significantly lower mortality rates among patients with DM who received DPP4i versus those who did not, a series of other studies showed no effect of DPP4i or even worse outcomes. A meta-analysis of 7 studies yielded a neutral estimate of the risk ratio of COVID-19-related mortality among users of DPP4i (0.81; 95% CI 0.57-1.15). Conclusion In the absence of randomized controlled trials, observational research available so far provides inconclusive results and insufficient evidence to recommend use of DPP4i against COVID-19.

show abstract

Section: Discussionmentioning

confidence: 89%

Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis

Bonora

Avogaro

Fadini

2021

J Endocrinol Invest

View full text Add to dashboard Cite

show abstract

“…Therefore, DPP-4 inhibitors are considered a novel means of treating T2DM. However, currently available DPP-4 inhibitors have several adverse effects such as arthritis, pancreatitis, diarrhea, and congestive heart failure that limit their practical applications (Mascolo et al, 2016;Packer, 2018;Padron et al, 2020), and thus, new DPP-4 inhibitors are needed. Computational techniques had shown to be effective in finding novel drugs and their development in the therapeutic development process (Katsila et al, 2016;Ali et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Dipeptidyl peptidase-4 inhibitory potentials of Glycyrrhiza uralensis and its bioactive compounds licochalcone A and licochalcone B: An in silico and in vitro study

Shaikh

Ali

Lim

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) is a growing global public health issue, and dipeptidyl peptidase-4 (DPP-4) is a potential therapeutic target in T2DM. Several synthetic anti-DPP-4 medications can be used to treat T2DM. However, because of adverse effects, there is an unmet demand for the development of safe and effective medications. Natural medicines are receiving greater interest due to the inherent safety of natural compounds. Glycyrrhiza uralensis (licorice) is widely consumed and used as medicine. In this study, we investigated the abilities of a crude water extract (CWE) of G. uralensis and two of its constituents (licochalcone A (LicA) and licochalcone B (LicB)) to inhibit the enzymatic activity of DPP-4 in silico and in vitro. In silico studies showed that LicA and LicB bind tightly to the catalytic site of DPP-4 and have 11 amino acid residue interactions in common with the control inhibitor sitagliptin. Protein-protein interactions studies of LicA-DPP4 and LicB-DPP4 complexes with GLP1 and GIP reduced the DPP-4 to GLP1 and GIP interactions, indicated that these constituents might reduce the degradations of GLP1 and GIP. In addition, molecular dynamics simulations revealed that LicA and LicB stably bound to DPP-4 enzyme. Furthermore, DPP-4 enzyme assay showed the CWE of G. uralensis, LicA, and LicB concentration-dependently inhibited DPP-4; LicA and LicB had an estimated IC50 values of 347.93 and 797.84 μM, respectively. LicA and LicB inhibited DPP-4 at high concentrations, suggesting that these compounds could be used as functional food ingredients to manage T2DM.

show abstract

Therapeutic application of natural compounds for skeletal muscle-associated metabolic disorders: A review on diabetes perspective

Ahmad,

Shaikh,

Lim

et al. 2023

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Republished: DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis

Cited by 7 publications

References 29 publications

Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis

Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis

Dipeptidyl peptidase-4 inhibitory potentials of Glycyrrhiza uralensis and its bioactive compounds licochalcone A and licochalcone B: An in silico and in vitro study

Therapeutic application of natural compounds for skeletal muscle-associated metabolic disorders: A review on diabetes perspective

Contact Info

Product

Resources

About